Companion Diagnostics for Anti-cancer


Companion Diagnostics for Anti-cancer

Home

Human Healthcare

Companion Diagnostics for Anti-cancer

Fecal Sampling

Microbiome Pattern Analysis

NGS* Analysis

Deep Learning

Immunotherapy Response Prediction

EPIOME predicts anticancer drug reactivity by analyzing microbiome patterns and NGS data through AI.
*NGS : Next-Generation Sequencing
Anti-cancer therapy requires a personalized approach, as each patient responds differently due to genetic and environmental factors.

Companion diagnostics for anticancer therapy analyzes patient biomarkers and genetic mutations to help select the optimal anticancer drug for each individual. This approach minimizes unnecessary side effects, increases treatment success rates, and reduces overall treatment costs. Rapid and accurate diagnostics enhance the entire treatment process and significantly improve patients' quality of life.


EPIOME utilizes deep learning technology to precisely analyze fecal microbiome patterns and predict anticancer responsiveness. This solution significantly reduces testing time, enhances cost-efficiency, and simplifies traditionally complex processes. Through accurate data analysis, it provides patients with the most suitable anticancer medication, playing a crucial role in improving treatment success rates. Additionally, it alleviates the burden on healthcare professionals and contributes to overall treatment efficiency. EPIOME’s innovative approach introduces a new paradigm in cancer treatment.